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A Novel Protein Glycan Biomarker and Future Cardiovascular Disease
Events
Akintunde O. Akinkuolie, MBBS, MPH; Julie E. Buring, ScD; Paul M Ridker, MD, MPH; Samia Mora, MD, MHS
Background-—Glycosylated proteins partake in multiple cellular processes including inﬂammation. We hypothesized that GlycA, a
novel biomarker of protein glycan N-acetyl groups, is related to incident cardiovascular disease (CVD), and we compared it with
high-sensitivity C-reactive protein (hsCRP).
Methods and Results-—In 27 491 initially healthy women, baseline GlycA was quantiﬁed by nuclear magnetic resonance
spectroscopy and hsCRP by an immunoturbidimetric assay. During median follow-up of 17.2 years, 1648 incident CVD events
occurred (myocardial infarction, ischemic stroke, coronary revascularization, and CVD death). GlycA and hsCRP were moderately
correlated (Spearman r=0.61, P<0.0001). In Cox regression models that included age, ethnicity, smoking, blood pressure,
medications, menopausal status, body mass index, and diabetes, hazard ratios for CVD across quartiles 1 to 4 of GlycA were 1.00,
1.10 (95% CI, 0.92 to 1.30), 1.34 (95% CI, 1.13 to 1.58), and 1.64 (95% CI, 1.39 to 1.93), similar to hsCRP, for which hazard ratios
were 1.00, 1.18 (95% CI, 0.99 to 1.41), 1.35 (95% CI, 1.14 to 1.61), and 1.75 (95% CI, 1.47 to 2.09) (both Ptrend<0.0001).
Associations were attenuated after additionally adjusting for lipids: the hazard ratio of quartile 4 versus 1 for GlycA was 1.23 (95%
CI, 1.04 to 1.46; Ptrend=0.002) and for hsCRP was 1.44 (95% CI, 1.20 to 1.72; Ptrend<0.0001). Further adjustment for the other
biomarker resulted in a hazard ratio of quartile 4 versus 1 for GlycA of 1.03 (95% CI, 0.85 to 1.24; Ptrend=0.41) and for hsCRP of
1.29 (95% CI, 1.06 to 1.56; Ptrend=0.001).
Conclusions-—In this prospective study of initially healthy women, baseline GlycA was associated with incident CVD, consistent
with a possible role for protein glycans in inﬂammation and CVD.
Clinical Trial Registration-—URL: http//clinicaltrials.gov/. Unique identiﬁer NCT00000479. ( J Am Heart Assoc. 2014;3:
e001221 doi: 10.1161/JAHA.114.001221)
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P ost-translational modiﬁcation of proteins enhances theirfunctional heterogeneity and is important for many
biological processes.1 The most common post-translational
modiﬁcation process is protein glycosylation, which involves
enzymatically adding a glycan (carbohydrate) moiety to the
protein.1 Recent studies have established the relevance of
glycosylated proteins to a variety of key biological processes,
including cell adhesion, molecular trafﬁcking and clearance,
signal transduction, and, importantly, modulation of the innate
immune system and control of immune cell homeostasis and
inﬂammation.2–4 Indeed, the mammalian “glycome” may even
be larger than the proteome and involves >1% of the genome
(>100 genes).2,5 Examples of clinically relevant glycans
include the human blood groups,4,6 the antithrombotic drug
glycan heparin,7 and most inﬂammatory proteins.8,9 Elabora-
tion of protein function via structural changes on their glycan
attachments has led to interest in targeting glycans as early
indicators of disease.9 To date, glycans have been difﬁcult to
measure in clinical populations because of their low plasma
concentrations and the lack of sensitive, rapid, and high-
throughput technology.
Protonnuclearmagnetic resonance (NMR) spectroscopy can
detect circulating levels of plasma glycoproteins by suppressing
resonance from high-molecular-mass plasma proteins.10
Through the initial work by Bell et al,10 proton NMR signals of
humanplasmawere assigned to uniqueN-acetylmethyl protons
of N-acetylated carbohydrate side chains that were covalently
linked to acute-phase plasma proteins. Furthermore, their work
suggested that glycoproteins of acute-phase reactants may be
useful for the detection, prognosis, and therapeutic monitoring
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of tissue damage marked by inﬂammation. Recently, Lipo-
Science Inc developed a research application called GlycA
which quantiﬁes the NMR signal that originates from the
N-acetyl methyl groups of the N-acetylglucosamine residues
located on speciﬁc glycan branches of particular plasma
proteins (mainly a1-acid glycoprotein, haptoglobin, a1-anti-
trypsin, a1-antichymotrypsin, and transferrin) (J. Otvos, PhD,
LipoScience Inc, personal communication, 2014). The proton
NMR spectra to which GlycA was assigned overlaps with
the region previously identiﬁed by Bell et al;10 hence, GlycA is
hypothesized to be a clinical marker of systemic inﬂamma-
tion and may also be a biomarker of cardiovascular risk.
To date, this hypothesis has not been tested in clinical
populations. To address this question, GlycA was measured
with NMR spectroscopy in 27 491 initially healthy women who
were followed prospectively for 17.2 years for incident cardio-
vascular disease (CVD) events.11,12 We aimed to examine the
association of baseline GlycA concentration with incident CVD
events and to compare it with another commonly used clinical
biomarker of chronic inﬂammation, high-sensitivity C-reactive
protein (hsCRP). In addition, we aimed to evaluate the joint
association of GlycA and hsCRP on the risk of future cardio-
vascular events to assess whether GlycA provided additional
clinical utility for the risk of future cardiovascular events beyond
the information conveyed by hsCRP.
Methods
Study Population
Study participants were from the Women’s Health Study, a
completed, randomized, double-blinded, placebo-controlled
trial of low-dose aspirin and vitamin E in the primary
prevention of CVD and cancer in women.11 Participants were
apparently healthy female health care professionals in the
United States who were aged 45 years or older and free of
self-reported CVD or cancer at study entry. All participants
provided written informed consent, and the institutional
review board of the Brigham and Women’s Hospital (Boston,
MA) approved the study protocol. At enrollment, participants
completed questionnaires on demographics, anthropometrics,
medical history, and lifestyle behaviors. A blood sample was
requested, but not required, from the 39 876 women who
were randomized; 28 345 women provided a sample. Of the
women who provided a blood sample at baseline, we obtained
both GlycA and hsCRP measurements for 27 491 participants
who were then included in the present study.
Laboratory Measurements
The blood samples obtained at enrollment were collected in
EDTA tubes and stored in vapor-phase liquid nitrogen
(170°C) until the time for laboratory analysis. GlycA signals
were quantiﬁed at LipoScience Inc from plasma NMR spectra
obtained from the automated NMR Proﬁler system. NMR
signal amplitudes originating from the N-acetyl methyl group
protons of the N-acetylglucosamine moieties located on the
bi-, tri-, and tetra-antennary branches of speciﬁc serum
proteins (mainly a1-acid glycoprotein, haptoglobin, a1-anti-
trypsin, a1-antichymotrypsin, and transferrin) were used to
calculate the concentrations of GlycA (lmol/L of N-acetyl
methyl groups). The GlycA NMR signal is centered at
2.000.01 ppm in the NMR spectra of plasma, and only N-
acetylglucosamine with speciﬁc glycosidic linkage, namely, b
(1?2) or b (1?6) with a preceding mannose residue,
contribute to the GlycA signal (J. Otvos, PhD, LipoScience Inc,
personal communication, 2014).
Measurement of hsCRP was performed with a high-
sensitivity immunoturbidimetric assay on the Hitachi 917
autoanalyzer (Roche Diagnostics), with reagents and calibra-
tors from Denka Seiken, as described previously.13 Standard
lipids were measured in a laboratory certiﬁed by the National
Heart, Lung, and Blood Institute and Centers for Disease
Control and Prevention Lipid Standardization Program, as
described previously.12,14
Assessment of Other Variables
Covariables of interest were self-reported on the question-
naire administered at study entry and included age, race or
ethnicity, smoking, menopausal status, postmenopausal hor-
mone use, parental history of premature myocardial infarc-
tion, use of cholesterol medication, history of diabetes
mellitus, and hypertension (physician diagnosis of hyperten-
sion, antihypertensive treatment, or self-reported systolic
blood pressure ≥140 mm Hg or diastolic blood pressure
≥90 mm Hg). Body mass index was calculated as the weight
in kilograms divided by the height in square meters.
Ascertainment of Cardiovascular Events
The primary end point of total CVD was ﬁrst cardiovascular
event as deﬁned in the Women’s Health Study protocol.11
This was a composite of nonfatal coronary heart disease
(CHD; nonfatal myocardial infarction and coronary revascu-
larization procedures), nonfatal ischemic stroke, and death
from cardiovascular causes. We separately examined the
composite end points of incident CHD (nonfatal myocardial
infarction, coronary revascularization, or coronary death) and
ischemic stroke. Information on the occurrence of these end
points was ascertained via annual follow-up questionnaires,
letters, and telephone calls. Following written informed
consent, medical records were obtained and reviewed by a
blinded end points committee for the adjudication of all
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reported end points based on predeﬁned criteria, as
described previously.11
Statistical Analysis
Statistical analyses were performed using SAS version 9.3
(SAS Institute). Baseline characteristics of participants across
the quartile distribution of GlycA were summarized as
medians (25th to 75th percentiles) for quantitative variables
and as percentages for qualitative variables. Comparisons
across quartiles were assessed with the Wilcoxon rank sum
test for quantitative variables and with v2 tests for qualitative
variables. Spearman coefﬁcients were used to correlate GlycA
and risk factors.
Person-years of follow-up were calculated, and Kaplan–
Meier survival curves were obtained according to quartiles
of GlycA and hsCRP. Cox proportional hazards regression
was used to determine hazard ratios (HRs) and correspond-
ing 95% CIs for incident events by quartiles and by 1 SD
for each biomarker. Multivariable adjusted models were
built in 3 stages. First we built a basic model adjusting for
age, race or ethnicity, smoking, systolic blood pressure,
hypertensive medication, cholesterol treatment, menopausal
status, hormone use, body mass index, diabetes, and
randomized trial assignments. The second model included
the basic-model variables plus standard lipids (low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol,
and natural logarithm [log]-transformed triglycerides). The
third model evaluated the potential role of inﬂammation on
the association between GlycA and events by additionally
adjusting the second model for hsCRP. The P value for
linear trend was computed by ﬁtting a continuous variable
that assigned the median value for each quartile in
regression models. Following satisfactory assessment of a
linear relation between GlycA and events by visual inspec-
tion of a plot of martingale residuals, we reﬁtted the
models by 1-SD increments in the biomarkers. Log-trans-
formed hsCRP values were used when analyzed as a
continuous variable.
Next, the joint association of GlycA and hsCRP on
cardiovascular events was evaluated by dividing participants
into 4 prespeciﬁed groups of high or low GlycA (greater than
top tertile or less than or equal to top tertile, ie, 399 lmol/L)
and high or low hsCRP (>3 or ≤3 mg/L) and was based on 9
prespeciﬁed groups according to low, medium, and high
concentrations, using tertiles of GlycA and the American
Heart Association and Centers for Disease Control and
Prevention cut points for hsCRP (<1, 1 to 3, and >3 mg/L).
Repeated analyses were also performed by applying the tertile
distribution of hsCRP. Interaction between GlycA and hsCRP
groups on incident events was performed by including the
cross product for GlycA (categorical) and hsCRP (categorical).
The proportional hazard assumption was tested by including
an interaction term between the follow-up time (log trans-
formed) and the biomarkers in relation to events. All
probability tests were 2-tailed, with values <0.05 considered
statistically signiﬁcant.
Results
Baseline Characteristics and Correlations
The mean age of the study population at baseline was 54.7
years (SD: 7.1 years). Median concentrations for GlycA and
hsCRP were 369 lmol/L (25th to 75th percentile: 326 to
416 lmol/L) and 2.03 mg/L (25th to 75th percentile: 0.81
to 4.38 mg/L), respectively. Increasing quartiles of GlycA
were associated with a higher prevalence of traditional
CVD risk factors and higher concentrations of hsCRP
(Table 1). GlycA correlated positively with hsCRP (Spearman
r=0.61, P<0.0001). GlycA also correlated positively in
increasing magnitude with age, low-density lipoprotein
cholesterol, body mass index, and triglycerides (Spearman
r=0.12 to 0.47, P for all <0.0001) and negatively with high-
density lipoprotein cholesterol (Spearman r=0.27,
P<0.0001).
Associations With Incident CVD
Over a median follow-up of 17.2 years, a total of 1648 CVD
events occurred (1089 CHD and 462 ischemic strokes).
Kaplan–Meier curves for CVD event–free survival diverged
according to quartiles of GlycA and hsCRP (Plog-rank<0.0001
for both) (Figure 1).
In Cox regression models that included age, ethnicity,
smoking, blood pressure, medications, menopausal status,
body mass index, diabetes, HRs for CVD across quartiles 1 to
4 of GlycA were 1.00, 1.10 (95% CI, 0.92 to 1.30), 1.34 (95%
CI, 1.13 to 1.58), and 1.64 (95% CI, 1.39 to 1.93), similar to
hsCRP, for which HRs were 1.00, 1.18 (95% CI, 0.99 to 1.41),
1.35 (95% CI, 1.14 to 1.61), and 1.75 (95% CI, 1.47 to 2.09)
(both Ptrend<0.0001) (Table 2). Associations were attenuated
after additionally adjusting for lipids: the quartile 4 versus 1
GlycA HR was 1.23 (95% CI, 1.04 to 1.46; Ptrend=0.002), and
the hsCRP HR was 1.44 (95% CI, 1.20 to 1.72; Ptrend<0.0001).
Further adjustment for the other biomarker resulted in
quartile 4 versus 1 HRs for GlycA of 1.03 (95% CI, 0.85 to
1.24; Ptrend=0.41) and for hsCRP of 1.29 (95% CI, 1.06 to
1.56; Ptrend=0.001). Similar results were obtained when the
biomarkers were examined as continuous variables per 1 SD,
except that GlycA remained signiﬁcantly associated with CVD
after adjusting for hsCRP (HR 1.08; 95% CI, 1.01 to 1.15;
P=0.02); the corresponding value for hsCRP was 1.16 (95% CI,
1.08 to 1.25; P<0.0001).
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Results of secondary analyses for GlycA and the individual
end points of CHD and ischemic stroke generally mirrored the
main results for CVD (Table 3).
Joint Analysis of GlycA and hsCRP With Incident
CVD
Kaplan–Meier curves for the joint analyses based on the 4
prespeciﬁed groups of high and low GlycA or hsCRP are
shown in Figure 2. The lowest rates of CVD-free survival was
signiﬁcantly associated with high levels for both GlycA and
hsCRP, and the highest rates of CVD-free survival were
signiﬁcantly associated with low levels of both biomarkers
(Plog-rank<0.0001). Of note, the survival rates for women who
had high levels of GlycA was indistinguishable by low or high
hsCRP levels until after 6 years of follow-up, when the survival
rates became evidently lower in women with high GlycA and
high hsCRP compared with those with high GlycA but low
hsCRP levels.
Joint analyses according to the 9 prespeciﬁed groups
based on GlycA tertiles and hsCRP clinical cut points are
shown in Figure 3. Compared with the referent group (GlycA
<341 lmol/L and hsCRP <1 mg/L), participants with GlycA
>399 lmol/L and hsCRP >3 mg/L had a multivariable-
adjusted HR of 1.34 (95% CI, 1.08 to 1.65; P=0.007). In
comparison, when examined separately based on these cut
points, the adjusted HR for GlycA was 1.19 (95% CI, 1.03 to
1.37; P=0.02), and for hsCRP was 1.30 (95% CI, 1.11 to 1.52;
P=0.001). There was no evidence of multiplicative interac-
tion between GlycA and hsCRP groups on incident CVD
(Pinteraction=0.13). Repeat analysis based on cut points derived
from hsCRP tertiles yielded essentially the same result.
Results of secondary joint analysis on the individual end
points of CHD and ischemic stroke were similar.
Sensitivity Analysis by Follow-Up Time
Because of a statistical interaction with time of follow-up
(P<0.05), we performed 2 additional sensitivity analyses by
Table 1. Baseline Characteristics According to Quartiles of GlycA
Quartiles of GlycA, lmol/L
≤326
n=6983
327 to 369
n=6797
370 to 416
n=6866
≥417
n=6845
Age, y 51 (48 to 57) 53 (49 to 59) 54 (49 to 60) 54 (50 to 60)
Race or ethnicity
White 94.5 95.6 95.7 95.0
Hispanic 1.0 1.2 1.1 1.0
Black 1.7 1.7 1.6 2.5
Other 2.8 1.59 1.6 1.1
Postmenopausal, % 46.0 53.8 58.0 60.7
Hormone use, % 36.8 41.7 46.4 49.9
Diabetes, % 1.1 1.7 2.4 5.5
Hypertension, % 14.5 20.8 27.0 38.5
Parental history of premature
myocardial infarction, %
11.9 12.4 12.8 14.3
Current smoking, % 7.7 10.6 12.6 15.8
Cholesterol treatment, % 1.3 2.3 3.2 6.0
Body mass index, kg/m2 22.9 (21.2 to 25.1) 24.2 (22.2 to 27.2) 25.7 (23.2 to 29.1) 27.5 (24.6 to 31.8)
hsCRP, mg/L 0.72 (0.35 to 1.54) 1.51 (0.72 to 2.89) 2.6 (1.4 to 4.6) 5.1 (2.8 to 8.3)
Hemoglobin A1c, % 4.9 (4.8 to 5.1) 5.0 (4.8 to 5.2) 5.0 (4.9 to 5.2) 5.1 (4.9 to 5.3)
Total cholesterol, mg/dL 197 (175 to 221) 207 (184 to 232) 213 (189 to 239) 219 (193 to 247)
LDL cholesterol, mg/dL 113 (94 to 133) 121 (101 to 144) 126 (104 to 148) 129 (106 to 152)
HDL cholesterol, mg/dL 57 (48 to 68) 53 (45 to 64) 50 (42 to 60) 47 (39 to 56)
Triglycerides, mg/dL 86 (65 to 116) 111 (82 to 154) 133 (97 to 186) 168 (120 to 236)
Values shown are medians (25th to 75th percentile) or percentages. P values were obtained from Wilcoxon rank sum test for quantitative variables and v2 tests for qualitative variables. All
P values for trend across quartiles were <0.001. HDL indicates high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein.
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follow-up time at or greater than 6 years, informed by a
somewhat different divergence pattern of the Kaplan–Meier
curves at 6 years versus later (Figures 1 and 2). In the
analysis restricted to 6 years of follow-up (422 CVD events;
Table 4), the association for quartile 4 versus 1 of GlycA with
CVD after adjusting for risk factors and hsCRP was HR 1.49
(95% CI, 1.01 to 2.19; Plinear trend=0.009). After adjusting for
risk factors and GlycA, the corresponding value for hsCRP and
CVD was HR 1.29 (95% CI, 0.85 to 1.96; Plinear trend=0.58).
Results were similar in models examining each biomarker as a
continuous variable. For participants with >6 years of follow-
up (n=26 697; 1226 CVD events), results were similar to that
of the main analysis.
Discussion
This prospective study of 27 491 initially healthy women
followed for a median of 17.2 years provides the ﬁrst
population-based evidence for the potential application of
protein glycan side-chain biomarkers to convey information
on incident CVD events. Speciﬁcally, we found that baseline
concentrations of GlycA, an NMR-measured protein glycan
biomarker, was associated with a graded increase in the risk
of incident CVD events in a manner and magnitude that was
comparable to that of hsCRP. Furthermore, the association of
GlycA with CVD was attenuated after adjusting for hsCRP,
consistent with a possible role for protein glycans in
inﬂammation and CVD.
An altered protein glycosylation pattern has been
described as a signiﬁcant event that occurs during the
transition from healthy to diseased tissue. Expansion of
biological information from the human genome into complex
cellular function occurs in part by post-translational modiﬁ-
cation of proteins. Protein glycosylation is the most ubiqui-
tous of these processes.1 The diverse forms of protein glycans
enable a range of physiological and pathological processes,
including inﬂammation, which is known to promote athero-
sclerosis.2,15,16 Harnessing clinical utility from the evolving
ﬁeld of glycobiology has been hampered by analytical
measurement difﬁculties related in part to the non–
template-driven nature of glycan biosynthesis, unlike biopoly-
mer counterparts (eg, proteins and nucleic acids). This
challenge is further complicated by the diversity of monosac-
charide structure, sequence, and linkage that is present in the
human glycome repertoire.17 NMR spectroscopy identiﬁes
unique protein glycans1,10 and thus may provide a high-
throughput and readily available technology for the quantita-
tive analysis of protein glycans.
The positive association between GlycA, a nonspeciﬁc
marker of systemic inﬂammation, and CVD risk factors, such
as smoking, body mass index, hypertension, and dyslipidemia,
suggest a role for modiﬁable lifestyle risk factors in the
expression of protein glycans that produce the GlycA signal.
Similar relationships with CVD risk factors were observed in a
prior study examining human plasma N-glycans measured
with another technique (high-performance liquid chromatog-
raphy).18 Speciﬁc glycosylation changes have also been
described for lipids. Low-density lipoprotein particles in
patients with CHD, for example, have reduced sialylation (a
type of glycosylation), which may make these low-density
lipoprotein particles more susceptible to subendothelial
retention, oxidative modiﬁcation, and atherosclerotic plaque
formation.19
Our observation that hsCRP attenuates the association of
GlycA, especially in the long term, suggests that GlycA may
convey CVD risk information, at least in part, through
inﬂammation. It is well described that glycan processing is
distinctly controlled during inﬂammation.2,15,16,20 Endothelial
cell dysfunction occurring as a result of a proinﬂammatory
stimuli, for instance, leads to pronounced changes in glycan-
processing mechanisms, which in turn direct speciﬁc glycan
expression patterns on isolated human endothelial cells.20 In
particular, proinﬂammatory stimuli have been shown to
GlycA
Plog-rank<0.0001
Plog-rank<0.0001
1st Quartile
2nd Quartile
3rd Quartile
4th Quartile
hsCRP
1st Quartile
2nd Quartile
3rd Quartile
4th Quartile
A
B
Figure 1. Kaplan–Meier curves of incident CVD according to
quartiles of GlycA (A) and hsCRP (B). Quartile concentrations were
≤326, 327 to 369, 370 to 416, and ≥417 lmol/L for GlycA and
≤0.81, 0.82 to 2.03, 2.04 to 4.38, and ≥4.39 mg/L for hsCRP.
CVD indicates cardiovascular disease; hsCRP, high-sensitivity
C-reactive protein.
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induce distinct changes in N-glycan processing mecha-
nisms.21–24 Adhesion molecules have also been shown to
be heavily glycosylated, and the associated glycans modulate
the interaction of adhesion molecules with their ligands.15,20
Furthermore, changes in endothelial cell glycosylation pat-
terns regulate the functions of adhesion molecules at sites of
early atherosclerotic plaque development. Indeed, proteins
associated with chronic inﬂammation not only experience
changes in their serum concentrations as a result of an
inﬂammatory stimulus but also are marked by alterations in
their glycan structures.8
It is worthy of note that GlycA is a composite NMR signal
arising from a subset of acute-phase reactants. As such, GlycA
signals originating from different glycoproteins or from the
same glycoprotein are indistinguishable by NMR. In other
words, measurement of GlycA from a given volume of plasma
does not provide information about the numbers of glycopro-
teins, the particular glycoform emitting the signal (given that
glycan conjugates may vary dynamically), or the contribution of
each glycoprotein to the GlycA signal. Based on known plasma
concentrations of each abundant glycoprotein and the number
of N-glycosylation sites present on each, Otvos and colleagues
estimated the relative contribution of known acute-phase
glycoproteins to the GlycA signal (J. Otvos, PhD, LipoScience
Inc, personal communication, 2014). This estimate yielded 5
major acute-phase glycoproteins that were then shown to
produce GlycA signals in proportion to their glycan N-acetyl
glucosamine concentrations (J. Otvos, PhD, LipoScience Inc,
personal communication, 2014). Their ﬁndings indicate that
a1-acid glycoprotein, haptoglobin, a1-antitrypsin, a1-antic-
hymotrypsin, and transferrin—all of which have been impli-
cated in the development of CVD18,25–30—make major
contributions to the GlycA signal. Biomarker proﬁling by NMR
spectroscopy in an Estonian Biobank study found a1-acid
glycoprotein to be signiﬁcantly predictive of cardiovascular
mortality, a ﬁnding that was validated in a replication cohort.18
In another recent study, investigators from the Framingham
Heart Study used a systems approach to biomarker discovery
and also found a1-acid glycoprotein to be 1 of 4 multimarker
proteins that signiﬁcantly predicted incident atherosclerotic
CVD.25 Regarding haptoglobin, functional genotypes have been
linked to CVD risk, with more limited data on the association of
circulating levels of haptoglobin with CVD.26,27 Furthermore,
the serine protease inhibitor a1-antitrypsin has also been
linked to CVD.28,29 However, the roles of a1-antichymotrypsin
(another serine protease inhibitor) and transferrin (an iron-
binding protein) are less well characterized with respect to
CVD. Other notable inﬂammatory proteins that have been
implicated in the development and manifestation of CVD
(ﬁbrinogen, CRP and interleukin-6)31 contribute negligibly to
the GlycA signal (J. Otvos, PhD, LipoScience Inc, personal
communication, 2014). Although it does not contribute much
to the GlycA signal, the CRP protein is glycosylated with glycan
attachments that exhibit disease speciﬁc changes.9
Table 2. Association of GlycA and hsCRP With Incident Cardiovascular Disease (n=1648 Events)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P Linear Trend Per 1 SD* P Value
GlycA
Range, lmol/L ≤326 327 to 369 370 to 416 ≥417
Incidence rate per
1000 person-years
2.1 2.9 4.1 6.2
Basic model 1.00 1.10 (0.92 to 1.30) 1.34 (1.13 to 1.58) 1.64 (1.39 to 1.93) <0.0001 1.26 (1.19 to 1.32) <0.0001
Basic model plus lipids 1.00 0.97 (0.81 to 1.16) 1.08 (0.91 to 1.28) 1.23 (1.04 to 1.46) 0.002 1.15 (1.08 to 1.21) <0.0001
Basic model plus lipids
plus hsCRP
1.00 0.91 (0.77 to 1.09) 0.97 (0.81 to 1.15) 1.03 (0.85 to 1.24) 0.41 1.08 (1.01 to 1.15) 0.02
hsCRP
Range, mg/L ≤0.81 0.82 to 2.03 2.04 to 4.38 ≥4.39
Incidence rate per
1000 person-years
2.0 3.1 4.0 6.2
Basic model 1.00 1.18 (0.99 to 1.41) 1.35 (1.14 to 1.61) 1.75 (1.47 to 2.09) <0.0001 1.28 (1.20 to 1.36) <0.0001
Basic model plus lipids 1.00 1.07 (0.89 to 1.27) 1.13 (0.95 to 1.35) 1.44 (1.20 to 1.72) <0.0001 1.21 (1.13 to 1.29) <0.0001
Basic model plus lipids
plus GlycA
1.00 1.04 (0.87 to 1.24) 1.06 (0.89 to 1.28) 1.29 (1.06 to 1.56) 0.001 1.16 (1.08 to 1.25) <0.0001
Basic model for each biomarker is adjusted for age, ethnicity, smoking, systolic blood pressure, hypertensive medications, cholesterol treatment, postmenopausal status, hormone use,
body mass index, diabetes, and trial treatment assignments. Lipids include low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and log triglycerides. SD is 68 lmol/L
for GlycA and 5.7 mg/L for hsCRP. hsCRP indicates high-sensitivity C-reactive protein.
*hsCRP was log transformed.
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Our ﬁnding of a time-dependent association of GlycA on
CVD risk was not prespeciﬁed and hence may be due to
chance. Additional studies will be needed to verify whether
GlycA conveys short- to medium-term CVD risk (up to
6 years) independent of hsCRP. Nonetheless, glycosylation
is a post-translational process that modiﬁes protein function
and is exquisitely responsive to the cellular milieu, which may
provide a biological explanation of this observation. In this
regard, it is possible that the glycan conjugates of acute-
phase glycoproteins that are captured as GlycA provide a
better signal of imminent events than longer term events
when compared with hsCRP. In addition, the small additive
association of GlycA and hsCRP with CVD risk suggests that
these biomarkers may play both overlapping and distinct roles
in the development of CVD. Noninﬂammatory proteins
implicated in CVD may also bear the glycan side chain that
is captured by the GlycA NMR signal. Apolipoprotein B, for
example, the major protein of atherogenic lipoproteins,
presumably contributes (albeit negligibly) to the novel GlycA
signal (J. Otvos, PhD, LipoScience Inc, personal communica-
tion, 2014).
Given the branched structure of glycan polymers, a
combination of a ﬁnite number of monosaccharides can give
rise to an exponential number of different glycan structures.
As such the NMR method may offer a unique technology to
harness important clinical information conveyed by the
expression of speciﬁc protein glycans, as shown in our study.
The molecular structure for any protein glycan with >1 glycan
attachment has yet to be deﬁned, given the inherent
difﬁculties in studying glycan structures.17 Enrichment of
the GlycA signal sites for molecular characterization will be
important for future insight into the diagnostic and therapeu-
tic potential of the related protein glycans.
Strengths of this study include the long prospective follow-
up (median 17.2 years) of a large number of participants
(N=27 491) with well-characterized cardiovascular health
markers and available biomarker phenotyping. The prospective
Plog-rank<0.0001
GlycA ≤399 μmol/L, hsCRP ≤3 mg/L
GlycA ≤399 μmol/L, hsCRP >3 mg/L
GlycA >399 μmol/L, hsCRP ≤3 mg/L
GlycA >399 μmol/L, hsCRP >3 mg/L
Figure 2. Kaplan–Meier curve of incident CVD according to joint levels of GlycA and hsCRP. High levels of
GlycA were deﬁned as greater than top tertile (>399 lmol/L). High levels of hsCRP were deﬁned as
>3 mg/L, according to clinical guidelines, which corresponded approximately to the top-tertile value in this
study. CVD indicates cardiovascular disease; hsCRP, high-sensitivity C-reactive protein.
A
dj
us
te
d 
H
az
ar
d 
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D
Figure 3. Hazard ratios for incident CVD events are shown on
the y-axis (log scale) for categories of GlycA and high-sensitivity
CRP (hsCRP). The hazard ratios are adjusted for age, ethnicity,
smoking, systolic blood pressure, hypertensive medications,
cholesterol treatment, postmenopausal status, use of hormone
replacement therapy, body mass index, history of diabetes, trial
treatment assignments, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol and log triglycerides. Categories of
GlycA are based on tertile cut points (<341, 341 to 399, and
>399 lmol/L). Categories of hsCRP are based on clinical cut
points (<1, 1 to 3, and >3 mg/L), as recommended by clinical
guidelines. CRP indicates C-reactive protein; CVD, cardiovascular
disease.
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nature of our observation deserves particular mention, given
that glycan conjugates may undergo dynamic structural
changes that are responsive to the phenotypic and metabolic
state of a cell.17 The standardized prospective ascertainment
of CVD events is also an important strength of our study.
Limitations of our study include the availability of blood only at
baseline, thus measurements of GlycA or hsCRP may not
reﬂect levels over a long period of time. In addition, general-
izability of our ﬁndings may be limited because our study
sample comprised female health professionals, who may have
different health behaviors than women in the general popula-
tion or men. Finally, the observational nature of this study
precludes our ability to rule out chance, residual confounding,
or confounding due to unmeasured variables. The results
presented are thus best viewed as hypothesis-generating data
and, as such, should be validated in other studies.
In conclusion, we have shown a signiﬁcant positive
association between baseline levels of N-acetyl methyl groups
of speciﬁc moieties of O- and N-linked protein glycans and
incident CVD events, an association which was attenuated
after adjusting for hsCRP, a biomarker of systemic inﬂamma-
tion. Although the results presented show promise for
the clinical application of glycobiology in CVD prevention,
the advent of new tools for glycoprotein analysis will aid the
structural characterization of glycans. Such research may
unlock the variety of prognostic, diagnostic, and therapeutic
opportunities that are yet untapped in the emerging ﬁeld of
glycobiology.
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